Vaccine makers urge FDA to include teens in vaccine Emergency Use Authorization
Jarryd Jaeger | The Post Millennial
According to a statement put out by Pfizer and BioNTech, they have jointly “requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech Vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age.”
Axios reports that the Pfizer BioNTech vaccine was found to be 100 percent effective in children in this age group, and that a trial has begun on children between 6 months and 11 years old.
Including younger people in the EUA would hasten the United States’ vaccine rollout, and put the country one step closer to herd immunity.